KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Aquestive Therapeutics (AQST) over the last 5 years, with Dec 2024 value amounting to $86.7 million.

  • Aquestive Therapeutics' Shares Outstanding (Diluted Average) rose 21.41% to $110.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.6 million, marking a year-over-year increase of 21.41%. This contributed to the annual value of $86.7 million for FY2024, which is 41.58% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Shares Outstanding (Diluted Average) of $86.7 million as of FY2024, which was up 41.58% from $61.3 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $86.7 million for FY2024, and its period low was $33.7 million during FY2020.
  • In the last 3 years, Aquestive Therapeutics' Shares Outstanding (Diluted Average) had a median value of $61.3 million in 2023 and averaged $65.6 million.
  • Data for Aquestive Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 41.58% (in 2024) over the last 5 years.
  • Aquestive Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $33.7 million in 2020, then grew by 13.15% to $38.1 million in 2021, then rose by 27.99% to $48.7 million in 2022, then increased by 25.69% to $61.3 million in 2023, then surged by 41.58% to $86.7 million in 2024.